Please login to the form below

Not currently logged in
Email:
Password:

Heptares

This page shows the latest Heptares news and features for those working in and with pharma, biotech and healthcare.

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

The drug is one of the lead candidate from a $3.35bn licensing deal Allergan agreed with Sosei’s Heptares Pharma subsidiary two years ago, covering global rights to a portfolio

Latest news

  • Pfizer signs high-level deal with GPCR specialist Heptares Pfizer signs high-level deal with GPCR specialist Heptares

    biologics drugs - and will pay up to $189m per project to Heptares as well as an undisclosed upfront payment. ... Pfizer's agreement with Heptares is notable because it spans so many targets and indications, according to the UK firm's chief executive

  • Teva buys into Heptares oral CGRP programme for migraine Teva buys into Heptares oral CGRP programme for migraine

    Signs$410m alliance for early-stage candidates in potentially-lucrative drug class. Teva will co-develop Heptares Pharma's portfolio of migraine therapies in a new alliance valued at up to $410m. ... The agreement - which includes a $10m upfront payment

  • AZ adds cancer vaccine to immuno-oncology portfolio AZ adds cancer vaccine to immuno-oncology portfolio

    The agreement comes hard on the heels of two other deals signed by AZ last week with Heptares and Mirati, which in turn extended a lengthening list of collaborations designed to

  • AZ signs two more deals in cancer immunotherapy AZ signs two more deals in cancer immunotherapy

    Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics.  . AstraZeneca continues to push its immuno-oncology programme hard, signing two new deals this week with Heptares and Mirati Therapeutics. ... AZ's MedImmune subsidiary has

  • Eastern Europe targeted

    Co-promotion in Japan. Targacept/AstraZeneca. TC-5619 in schizophrenia. Decline of option. Heptares Therapeutics/Shire. ... Heptares signed an exclusive option to a worldwide licence with Shire for its adenosine A2A antagonist, which is in preclinical

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    Dr Fiona Marshall has joined MSD from Heptares Therapeutics, the UK biotech company she co-founded more than a decade ago, which was acquired by Sosei in 2015.

  • Deal Watch March 2017 Deal Watch March 2017

    rights to Heptares’ G protein-coupled receptor product for pain relief. ... 20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.

  • Deal Watch April 2016 Deal Watch April 2016

    Allergan must have known for some time that the Pfizer acquisition was likely to collapse because on the same day as the announcement, Allergan announced a $3.3bn deal with Heptares ... 9, 800. Heptares (JP). Allergan (IE). License and collaboration.

  • Deal Watch November 2015 Deal Watch November 2015

    455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine. ... 225. Heptares. Pfizer. Strategic discovery collaboration. New therapeutics against up to 10 GPCR targets across

  • Pharma deals in August 2015 Pharma deals in August 2015

    AstraZeneca deals. Subject. Headline $m. Inovio. Cancer vaccines. 727. Heptares. HTL 1071 and A2A receptor blocking compounds. ... The deal brings an upfront of $10m to Heptares with a further $500m and tiered double digit royalties.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Metrion Biosciences adds to its board Metrion Biosciences adds to its board

    Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

  • Sosei appoints chief operating officer Sosei appoints chief operating officer

    He has served as a non-executive director at Sosei since 2010, and has since worked at Syngene International, where he was chief executive and executive director, and Heptares Therapeutics, where

  • Former Amgen EVP Roger Perlmutter joins Heptares board Former Amgen EVP Roger Perlmutter joins Heptares board

    Also has experience at Merck &Co. Heptares has appointed Amgen's former executive VP, R&D, Dr Roger Perlmutter, to its board of directors. ... Dr Perlmutter said: “Heptares has pioneered structure determination in GPCRs, and has used this information

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics